This biotech stock could see a sharp swing higher after years of struggling, charts suggest

Biogen (BIIB) stock is exhibiting a potential technical breakout, attempting to clear a bullish cup-and-handle formation and its 200-day moving average, a level not meaningfully surpassed since 2023. This current rally is differentiated from a failed 2024 attempt by the stock breaking above a 10-year downtrend line and its historically oversold monthly RSI, which is at its lowest point ever. A sustained move above the $137 area could trigger an upside target near $164, marking a crucial initial step in reversing a prolonged downturn for the biotech firm.

Analysis

Biogen (BIIB) is at a critical technical inflection point, attempting to break out from a bullish cup-and-handle formation following a roughly 25% rally from its April lows. The stock is concurrently testing its 200-day moving average, a significant resistance level it has failed to sustain a position above since 2023. A successful breakout above the $137 area is identified as the trigger for a potential move toward an upside target near $164. This current rally attempt is distinguished from a similar failed breakout in 2024 by two key factors. First, BIIB is now breaching a steep 10-year downtrend line, a development that has historically preceded strong upward price action. Second, the advance originates from a historically oversold condition, with its 14-month RSI recently recording its lowest reading since the early 1990s, suggesting the potential for a powerful snapback rally. While the stock's long-term downtrend remains intact, the confluence of a short-term bullish pattern, a break of a multi-year trendline, and an unprecedented oversold state presents a compelling technical argument for a potential trend reversal.

Key Decisions for Investors

• Investors should closely monitor BIIB's ability to decisively close and hold above the $137 level and its 200-day moving average, as a failure to sustain this breakout could signal a repeat of the unsuccessful 2024 rally attempt.
• For those considering a bullish position, the combination of a 10-year downtrend line break and a historically oversold monthly RSI provides a strong technical rationale, with an initial price objective near $164.
• Given the stock's history of failed rallies, it is prudent to manage risk by considering a close below the 200-day moving average as a potential signal to exit or reduce the position, confirming that the breakout has lost momentum.